Trial Profile
A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Erdafitinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 27 May 2019 Status changed from active, no longer recruiting to completed.
- 04 Apr 2019 Planned End Date changed from 28 Feb 2019 to 31 Jul 2019.
- 04 Apr 2019 Planned primary completion date changed from 28 Feb 2019 to 17 Jul 2019.